Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
, 19 (5), 685-708

Assessment of Patients With Systemic Lupus Erythematosus and the Use of Lupus Disease Activity Indices

Affiliations
Review

Assessment of Patients With Systemic Lupus Erythematosus and the Use of Lupus Disease Activity Indices

Bridget Griffiths et al. Best Pract Res Clin Rheumatol.

Abstract

The assessment of disease activity in systemic lupus erythematosus (SLE) is a task faced by clinicians in every day care, but it is also required for clinical research and in randomised controlled trials. It is crucial to distinguish disease activity from infection, chronic damage and co-morbid disease. Over the past 20 years, many indices have been developed to objectively measure lupus disease activity and several of these have been validated. The most widely used indices are the British Isles Lupus Assessment Group (BILAG) index, the European Consensus Lupus Activity Measurement (ECLAM), the Systemic Lupus Activity Measure (SLAM), the Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) and the Lupus Activity Index (LAI). All these indices have been validated and have excellent reliability, validity and responsiveness to change. In addition to the assessment of disease activity, the evaluation of damage using the validated SLICC/ACR damage index and health-related quality of life is advised for clinical research.

Similar articles

See all similar articles

Cited by 68 articles

See all "Cited by" articles

MeSH terms

LinkOut - more resources

Feedback